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Although themicroglial activation is concomitant to theAlzheimer’s disease, its precise role (neuroprotection vsneurodegeneration) has
not yet been resolved.Here, we show the existence of an age-dependent phenotypic change ofmicroglial activation in the hippocampus of
PS1xAPP model, from an alternative activation state with A phagocytic capabilities (at 6 months) to a classic cytotoxic phenotype
(expressing TNF- and related factors) at 18 months of age. This switch was coincident with high levels of soluble A oligomers and a
significantpyramidalneurodegeneration. In vitroassays, usingastromicroglial cultures, demonstrated that oligomericA42andsoluble
extracts from 18-month-old PS1xAPP hippocampus produced a potent TNF- induction whereas monomeric A42 and soluble extract
from6-or 18-month-old control and6-month-oldPS1xAPPhippocampiproducedno stimulation. This stimulatory effectwas avoidedby
immunodepletion using 6E10 or A11. In conclusion, our results show evidence of a switch in the activated microglia phenotype from
alternative, at thebeginningofApathology, to a classical at advanced stageof thedisease in thismodel. This changewas induced, at least
in part, by the age-dependent accumulation of extracellular solubleA oligomers. Finally, these cytotoxic activatedmicroglial cells could
participate in the neuronal lost observed in AD.
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Introduction
As proposed by the inflammation hypothesis of Alzheimer’s dis-
ease (AD), the neurodegenerative process could be exacerbated
by a chronic inflammatory response to -amyloid (A) peptides
(for review, see Griffin et al., 1998; Wyss-Coray, 2006; Heneka
and O’Banion, 2007). Secondary to A accumulation, there is an
inflammatory response characterized by activated microglia and
reactive astrocytes. Activated inflammatory cells could mediate
neuronal damage by producing toxic products, such as inflam-
matory cytokines, excitatory amino acids, reactive oxygen inter-
mediates and other factors (Mrak and Griffin, 2005; Craft et al.,
2006; Ralay Ranaivo et al., 2006; Zipp and Aktas, 2006). This
potential cytotoxic effect was further emphasized by clinical stud-
ies demonstrating that the symptoms of AD could be attenuated
by nonsteroidal antiinflammatory drugs (Aisen, 2000; McGeer
and McGeer, 2007). However, recent trials have not confirmed
this positive effect (Aisen et al., 2003; Reines et al., 2004).
Although a deleterious inflammatory reaction could indeed
mediate the neurodegeneration in AD, a completely different
possibility is just beginning to be considered, supporting a tro-
phic, proregenerative role of the inflammatory response. Acti-
vated glial cells are also capable to secrete anti-inflammatory cy-
tokines (Butovsky et al., 2006), as well as neuroprotective factors
that may protect against AD pathology (Streit, 2005). In this
sense, vaccination against the A peptides led to activation of
microglia and successfully decreased amyloid load (Wilcock et
al., 2003, 2004a,b). Similarly, stimulating the immune system
with lypopolisaccharide (LPS) led to a reduction in A plaques
(DiCarlo et al., 2001;Herber et al., 2004). Nevertheless, at present
little information is known about the balance between procyto-
toxic and anticytotoxic events occurring in AD or about the cel-
lular and temporal induction of inflammatory cascade by A.
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Transgenic (tg) mice models are widely used to study AD
pathology. We have previously characterized a double PS1xAPP
tg mouse. These transgenic mice developed early (3–4 months)
hippocampal A plaques (Blanchard et al., 2003; Ramos et al.,
2006; Caballero et al., 2007). In parallel with A deposition, we
also demonstrated the existence of degeneration of a particular
subset of hippocampal GABAergic neurons (O-LM and HIPP
cells; Ramos et al., 2006). However, despite the age-dependent
accumulation of extracellular A (Blanchard et al., 2003; Ramos
et al., 2006; Caballero et al., 2007), no significant pyramidal de-
generation was detected until 17–18 months of age (Schmitz et
al., 2004; Ramos et al., 2006; unpublished results). Thus, it is
possible that in the AD tg models the A pathology could be
attenuated until relatively old ages. In this work, we determined
the in vivo inflammatory response in the hippocampus of
PS1xAPP tgmice fromawide age range (from2 to 18months). At
early ages (6 months), we have observed the activation of the
microglial cells to an alternative phenotype, exclusively, sur-
rounding the A plaques. However, at 18 months of age, ex-
panded microglial activation throughout all hippocampal layers
displaying a classic cytotoxic phenotypewas observed. Finally, we
also investigated the reasons that could determine this age-
dependent microglial phenotypic change.
Materials andMethods
Transgenic mice. The generation and initial characterization of the
PS1M146L (PS1) and PS1xAPP751sl (PS1xAPP) tg mice have been re-
ported previously (Blanchard et al., 2003). PS1 tg mice (C57BL/6 back-
ground) overexpressed the mutated PS1M146L form under the control
of the HMGCoA-reductase promoter. PS1xAPP double tg mice
(C57BL/6 background) were generated by crossing homozygotic PS1 tg
micewith heterozygotic Thy1-APP751SLmice (all tgmicewere provided
by Transgenic Alliance-IFFA-Credo). Mice represented filial generation
10–15 (F10–F15) offspring of heterozygous tg mice. Only male mice
were used in this work. Age-matched non-transgenic male mice of the
same genetic background (C57BL/6) were used as controls (WT).
Anesthetized mice were killed by decapitation, and both hippocampi
were dissected, frozen in liquid N2, and stored at 80°C until use. All
animal experiments were performed in accordance with the guidelines of
the Committee of Animal Research of the University of Seville (Spain)
and the European Union Regulations.
RNA and total protein extraction. Total RNA was extracted using the
Tripure Isolation Reagent (Roche) as described previously (Ramos et al.,
2006; Caballero et al., 2007). The contaminating DNA in the RNA sam-
ples was removed by incubation with DNAase (Sigma-Aldrich) and con-
firmed by PCR analysis of total RNA samples prior reverse transcription
(RT). After isolation, the integrity of the RNA samples was assessed by
agarose gel electrophoresis. The yield of total RNA was determined by
measuring the absorbance (260 of 280 nm) of ethanol-precipitated ali-
quots of the samples. The recovery of RNA was comparable in all groups
(1.2–1.5 g/mg tissue).
The protein pellets, obtained using theTripure IsolationReagent, were
resuspended in 4% SDS and 8 M urea in 40 mM Tris-HCl, pH 7.4, and
rotated overnight at room temperature (Ramos et al., 2006; Caballero et
al., 2007).
Retrotranscription and real-time RT-PCR. The retrotranscription was
done using random hexamers, 3 g of total RNA as template and High-
Capacity cDNA Archive Kit (Applied Biosystems) following the manu-
facturer recommendations (Ramos et al., 2006; Caballero et al., 2007).
For real time RT-PCR, each specific gene product was amplified using
commercial Taqman probes, following the instruction of the manufac-
turer (Applied Biosystems), using an ABI Prism 7000 sequence detector
(Applied Biosystems). For each assay, a standard curve was first con-
structed, using increasing amounts of cDNA. In all cases, the slope of the
curves indicated optimal PCR conditions (slope 3.2–3.4). The cDNA
levels of the different mice were determined using two different house-
keepers [i.e., glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
-actin]. The amplification of the housekeepers was done in parallel with
the gene to be analyzed. Similar results were obtained using both house-
keepers. Thus, the results were normalized using only the GAPDH
expression.
Independently of the gene analyzed, the results were always expressed
using the comparative Ct method, after the Bulleting number 2 from
Applied Biosystems. As a control condition, we selected 6-month-old
WT mice. In consequence, the expression of all tested genes, for all ages
and mice types, was referenced to the expression levels observed in
6-month-old WT mice.
Peptide preparation. To prepare the A42 peptides, we allowed syn-
thetic lyophilized A1–42 peptide (human sequence; AnaSpec) to equil-
ibrate, at 2023°C, for 30min before it was resuspended and diluted to 1
mM in 1,1,1“,3,3,3”-hexafluoro-2-propanol. After evaporation, peptide
films were dried in a Speed Vacuum and stored at40°C. Peptide films
were resuspended to 5mM in dimethyl sulfoxide (DMSO) for 10min. To
form the ADDLs (Lambert et al., 2001), we diluted the 5 mM DMSO
solution to 100 M in cold PBS, vortexed for 30 s, and incubated over-
night at 4°C. Before use, the A-PBS solution was further diluted in
culturemedia. The presence of ADDLs was tested byWestern blots using
6E10 (data not shown).
To form the monomers, immediately before use, we diluted the 5 mM
DMSO solution in PBS (to a final concentration of 100M), followed by
ultrafiltration through 5 kDa cutoff device (Vivaspin 2; Sartorius Biolab
Products). The presence of the monomeric A42 peptide (Mr 4.5 kDa)
was verified by Western blots (data not shown).
Soluble protein extraction. The soluble fractions (S1) were obtained by
ultracentrifugation of the homogenates as described previously (Kayed et
al., 2003). Briefly, tissue samples were homogenized (using a Teflon-glass
homogenizer) in cold PBS [containing a mixture of protease inhibitors
(Sigma-Aldrich)] and ultracentrifuged (OptimaMAXPreparativeUltra-
centrifuge; Beckman Coulter) at 120,000  g, 4°C, during 60 min. Im-
mediately after centrifugation, the samples were aliquoted and stored at
81°C until use. The protein content in the soluble fractions was deter-
mined by Lowry.
Western blot and dot blot.Western blots were performed as described
previously (Araujo et al., 1996). Briefly, 20g of protein from the differ-
ent samples were loaded on 16% SDS-Tris-Tricine-PAGE and trans-
ferred to nitrocellulose (Hybond-C Extra; Amersham). After blocking,
the membranes were incubated overnight, at 4°C, with the appropriate
antibody (monoclonal 6E10, Sigma-Aldrich; dilution 1:2000). Themem-
branes were then incubated with anti-mouse horseradish-peroxidase-
conjugated secondary antibody (Dako) at a dilution of 1:8000. The blots
were developed using the ECL-plus detection method (Amersham).
Dot-blots were done as described previously (Araujo et al., 1996; Lam-
bert et al., 2007). One microgram of protein from the different soluble
fractions was directly applied to dry nitrocellulose in a final volume of 2
l. Blots were air-dried, blocked for 1 h, and incubated overnight at 4°C,
with either Nu-1 (courtesy of Dr. W. Klein, Northwestern University,
Evanston, IL; 1 g/ml) or A11 (1:5000 dilution; Biosource) antibodies.
After the incubation, the blots were washed and visualized as described
above. For quantification, the scanned (Epson 3200) images were ana-
lyzed using PCBAS program. In each experiment, the intensity of dots
fromWTmice were averaged and considered as background of the cor-
responding age group.Datawere always normalized by the specific signal
observed in 6-month-old PS1xAPP group.
Tissue preparation. After deep anesthesia with sodium pentobarbital
(60 mg/kg), 2-, 4-, 6-, 12-, and 18-month-old WT and PS1xAPP tg male
mice were perfused transcardially with 0.1MPBS, pH 7.4 followed by 4%
paraformaldehyde, 75 mM lysine, 10 mM sodium metaperiodate in 0.1 M
phosphate buffer (PB), pH 7.4. Brains were then removed, postfixed
overnight in the same fixative at 4°C, cryoprotected in 30% sucrose,
sectioned at 40 m thickness in the coronal plane on a freezing mic-
rotome and serially collected in wells containing cold PBS and 0.02%
sodium azide. Each experiment was composed of 3–6 sets of animals
(each one containing one WT and one PS1xAPP tg mice). All animal
experiments were approved by the Committee of Animal Use for Re-
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search of the Malaga University (Spain) and the European Union
Regulations.
Immunohistochemistry. Coronal free-floating sections (40 m thick)
from WT and PS1xAPP hippocampus were first treated with 3%
H2O2/3% methanol in PBS and with avidin-biotin Blocking Kit (Vector
Labs). For single immunolabeling, sections were incubated overnight at
room temperature with one of the following primary antibodies: mouse
monoclonal anti-A 6E10 (1:1500 dilution; Sigma), rat monoclonal
anti-CD11b (1:150,000; Serotec), chicken polyclonal anti-GFAP
(1:10,000; Dako), hamster monoclonal anti-CD3 (1:100; BD PharMin-
gen), rat monoclonal anti-TNFalpha (1:100; Abcam), rabbit polyclonal
anti-iNOS (1:1000; Transduction Laboratories), goat polyclonal anti-IL4
(1:250 dilution; SantaCruz), and goat polyclonal anti-AMCase (YM-1;
1:100 dilution; SantaCruz). The tissue-bound primary antibody was de-
tected by incubating with the corresponding biotinylated secondary an-
tibody (1:500 dilution; Vector Laboratories), and then followed by
streptavidin-conjugated horseradish peroxidase (Sigma-Aldrich), di-
luted 1:2000. The peroxidase reaction was visualized with 0.05% 3-3-
diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich), 0.03%
nickel ammonium sulfate, and 0.01% hydrogen peroxide in PBS. Some
immunolabeled sections were then incubated for 3 min in a solution of
20%Congo red. Sectionswere thenmounted on gelatin-coated slides, air
dried, dehydrated in graded ethanols, cleared in xylene and coverslipped
with DPX (BDH) mounting medium. Specificity of the immune reac-
tions was controlled by omitting the primary antiserum.
For double immunofluorescence labeling (GFAP-6E10, GFAP-iNOS,
GFAP-IL4, or CD3-IL4), sections were first sequentially incubated with
the primaries antibodies (see antibodies above listed), followed by the
corresponding Alexa488/Alexa568-conjugated secondary antibodies (1:
1000 dilution, Invitrogen) or by biotinylated secondary antibody (1:500;
Vector Laboratories) and streptavidin-conjugated Alexa488/568 (1:2000
dilution; Invitrogen). For double CD11b-Thioflavin-S, YM1-Tomato
lectin, 6E10-Tomato lectin or IL4-Tomato lectin, fluorescence labeling,
sections were first incubated with the primary antibody followed by Al-
exa568 or Alexa488 conjugated secondary antibody. Then, sections were
washed and processed for thioflavin-S staining (see below) or incubated
for 1 h with a solution of 5 g/ml biotinylated Tomato lectin (Sigma)
followed by streptavidin-conjugated Alexa 568 (1:1000; Invitrogen). Sec-
tions were mounted onto gelatin-coated slides, coverslipped with 0.01 M
PBS containing 50% glycerin and 2.5% triethylenediamine and then ex-
amined under a confocal laser microscope (Leica TCS-NT).
Thioflavin S staining. Free-floating sections were incubated for 5 min
with 0.015% Thio-S (Sigma) in 50% ethanol, and then washed in 50%
ethanol, mounted onto gelatin-coated slides and coverslipped with
0.01M PBS containing 50% glycerin and 2.5% triethylenediamine.
Plaque loading and plaque size distribution.Hippocampal 6E10 immu-
nostaining from 2-, 4-, 6-, 12-, and 18-month-old PS1xAPP mice was
observed under a Nikon Eclipse 50i microscope using a 4 objective and
images acquired with a Nikon DS-5M high-resolution digital camera.
The camera settings were adjusted at the start of the experiment and
maintained for uniformity. Digital images (seven sections permouse and
six mice per age group) were analyzed using Visilog 6.3 analysis program
(Noesis). The plaque area within the hippocampus was identified by
bright-level threshold, the level of which was maintained throughout the
experiment for uniformity. The gray-scale image was converted to a
binary image with plaque and hippocampal field areas identified. Plaque
loading was defined as percentage of total hippocampal area stained for
A, excluding principal cell layers intracellular labeling thatwas removed
bymanual editing. The hippocampal area in each 4imagewasmanually
outlined. The plaque loading (percentage) for each tg mouse was esti-
mated and defined as (sumplaque areameasured/sumhippocampal area
analyzed)100. The sumswere taken over all slides sampled and a single
plaque burden was computed for each mouse. The mean and SD of the
plaque loading were determined using all the available data. Quantitative
comparisons were performed on sections processed at the same time.
For -amyloid plaque morphometric analysis (surface area), three
coronal sections immunostained with 6E10 from 6- (n 3), 12 (n 3)
and 18-month-old (n  3) PS1xAPP mice were analyzed using the nu-
cleator method with isotropic probes by the NewCast software package
from Olympus sterological system. Hippocampal CA1 subfield (9 sec-
tions per age) was analyzed using a counting frame of 7154.7 m2 and
step lengths of 299.55 225.54m. For individual plaquemeasurement
we used the 40 objective. Number of plaques/mm2 falling into four
surface categories (ranging from200 m2 to2000 m2) was calcu-
lated. Each analysis was done by a single examiner blinded to sample
identities.
Stereology.Cresyl-violet stained CA1 principal cell nuclei belonging to
6-, 12-, and 18-month-old WT and PS1xAPP mice (n  6/group/age;
10–15 sections per animal) were quantified according to the optical frac-
tionatormethod, using anOlympus BX51microscope (Olympus), inter-
faced with a computer and a color JVC digital videocamera. The CAST-
Grid software package (Olympus) generated sampling frames with a
known area (aframe) anddirected themotorizedX-Y stage (Prior Proscan;
Prior Scientific Instruments), and a microcator (MT12; Heidenheim),
which monitored the movements in the z-axis with a resolution of 0.5
m. The number of neurons was quantified in every seventh section
(with a distance of 280 m) through the entire anteroposterior extent of
the hippocampus (between 0.94 mm anterior and 3.64 mm posterior
to Bregman according to the atlas of Paxinos andWatson). This selection
criteria prevented counting neurons from contiguous sections. CA1 sub-
field was defined using a 10 objective and the number of principal cells
was counted using a 100/1.35 objective. Each counting frame was
2342.8 m2. We used the optical 3 m from the upper surfaces as look-
up, and those 3–13 m from the surfaces as reference sections. The
software calculated the estimated total number of cresyl-violet stained
nuclei in the CA1 region using the optical fractionator formula (West et
al., 1991; Schmitz and Hof, 2005), N  1/bsf.1/ssf.1/asf.1/hsf.Q,
where bsf is the block sampling fraction, ssf represents the section sam-
pling fraction, asf is the area sampling fraction, which is calculated by
dividing the area sampled with the total area of the layer, hsf stands for
the height sampling fraction, which is calculated by dividing the height
sampled (10m in this study) with the section thickness, andQ is the
total count of nuclei sampled for the entire layer. The precision of the
individual estimations is expressed by the coefficient of error (CE) (Gun-
dersen et al., 1999) and here we have estimated the total CE (CE group
value) that was calculated using the CEs in each individual animal. The
CEs ranged between 0.03 and 0.07.
The numerical density (Nv) of activated microglial cells (number of
cells per mm3) was determined in the CA1 subfield using the NewCast
Grid Stereological System from Olympus. For each animal from 6- (n
3) and 18- (n  3) month-old PS1xAPP, activated microglial cells were
quantified with the optical dissector method in two slices immuno-
stained with anti-CD11b at1.82 mm and 2.30 mm from the Bregman
according to the atlas of Paxinos andWatson. Each section was analyzed
using a systematically random manner, the counting frame was 29,031
m2 and step lengths of 121.06  91.15 m. CA1 subfield was defined
using a 4 objective and the number of activated microglia cells was
counted using a 100/1.35 objective.We used the optical 3m from the
upper surfaces as look-up, and that 3–13 m from the surface as refer-
ences sections and optical dissector height was 10 m. The Nv of micro-
glial cells per mm3 was calculated by using the following equation: Nv
Q/a  h. Where Q is the number of activated microglial cells per
counting box, a is the area of the counting frame, and h is the height of the
optical dissector. The average number of cells per mm3 was derived for
each section. Animal means were derived by averaging the Nv from two
sections from each animal in the CA1 subfield.
Astro-microglial cultures.Mixed astromicroglial primary cultures were
prepared from newborn C57BL/6 mice (1–3 d). Briefly, dissected brains
were treated, for 5 min, with trypsin-DMEM-EDTA medium (Biowhit-
taker, Cambrex). The treatment was stopped using complete DMEM-
F12 plus 10% FBS and the cells were mechanically dissociated. After
mechanical dissociation, the debris were eliminated by filtration (40m;
BD Falcon) and the cells were seeded (at a density of 250.000 cells/ml) in
DMEM-F12 plus 10% FBSmedium (containing glutamine, nonessential
amino acids, 1% penicillin-streptomycin and gentamycin) on poly-D-
lysine (Sigma-Aldrich) -treated Nunc 12-well plates. The cells were cul-
tured at 37°C, in humidified 5% CO2/95% atmosphere. Medium was
replaced every 4 d. After 13–15 d in culture, the mixed glial cultures were
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treated with different concentrations (ranging from 1 to 50 M) of AD-
DLs or monomeric A42, prepared as described above. The cells were
then incubated for 3 h. Control cultures (twowells per plate)were treated
with equivalent volume of sterilized PBS (negative control) or 1 g/ml
LPS (E. coliO26:B6; Sigma-Aldrich) as positive control. The S1 from the
differentmice and ageswere thawed immediately before use, dilutedwith
DMEM-F12 (without FBS), sterilized by filtration (through 0.22 m
filters; Millipore), and added to the cultures (ranging from 5 to 100g of
protein). For each experiment, duplicate wells were stimulated under the
same experimental condition.
The immunodepletion experiments were done basically as described
previously (Araujo et al., 1996). Briefly, 10 g of protein from S1 frac-
tions from 18-month-old PS1xAPPmice (n 3) were subjected to three
sequential incubations (8–12 h at 4°C) with either 6E10 (2 g)-Protein
G-Sepharose or A11(2 g)-Protein-A-Sepahrose immunocomplexes.
After immunodepletion, the S1 fractions were treated as above. As con-
trol, the different S1 fractions were sequentially incubated with either
Protein G-Sepharose or Protein A-Sepharose and tested, in parallel ex-
periments, with the immunodepleted samples.
After incubation, the cultures were treated with Tripure and RNAwas
isolated and retrotranscribed as described above.
Statistical analysis. Data were expressed as mean  SD. The com-
parison between two mice groups (WT and PS1xAPP tg mice) was
done by two-tailed t test. For comparison between several age groups,
we used one-way ANOVA followed by Tukey’s post hocmultiple com-
parisons test (Statgraphics plus 3.1). The significance was set at 95%
of confidence.
Results
Phenotypic characterization of microglial cells in 6- and
18-month-old PS1xAPP
Coincident with the apparition of the extracellular A plaques (4
months of age; data not shown), we observed a remarkable mi-
croglial activation in the hippocampus of PS1xAPPmice (supple-
mental Fig. 1, available at www.jneurosci.org as supplemental
material). Numerous CD11b-positive activated microglial cells,
showing a marked cellular hypertrophy and thicker and shorter
processes, were concentrated surrounding and infiltrating theA
plaques (Fig. 1A; supplemental Figs. 1C, 2, available at www.
jneurosci.org as supplemental material). However, at these early
ages (4–6 months) most microglial cells no associated to A
plaques, which were also CD11b-positive, displayed a quiescent
or restingmorphology, with small compact somata bearingmany
long thin ramified processes (Fig. 1A, a1, inset).
Microglia could adopt several different phenotypes. The mi-
croglial activation by A peptides has been associated with the
production of proinflammatory and potentially toxic cytokines
(Heneka and O’Banion, 2007). Thus, we quantitatively deter-
mined themRNAexpression of proinflammatory factors, includ-
ing Il-1; TNF- and TNF- related factors (TRAIL and FASL);
iNOS; Cox2 and Nox1. As shown (Fig. 1B), in 6-month-old
PS1xAPP mice, none of the classic proinflammatory and cyto-
Figure 1. Phenotypic characterization of the activatedmicroglial cells in PS1xAPPmice hippocampus at 6 and 18months of age. A, Highmagnification of CD11b positivemicroglial cell in 6 (a1)
and 18month (a2) PS1xAPPmice. At 6months of age (a1), the activatedmicroglial cells weremostly restricted to the A plaques (asterisks) whereas the interplaquemicroglia displayed a resting
morphology (a1, inset). At 18months of age (a2), both plaque-associated and interplaquemicroglia displayed an activatedmorphology. The inset displays an interplaque activatedmicroglial cell.
B,C, The expression of classic (B) activationmarkers ofmicroglial cells and themRNAexpression of genes consideredmarkers of the alternative activation (C)were quantitatively determined (by real
timeRT-PCR) in 6- and 18-month-oldWTandPS1xAPPmice (10mice permice group and age). The expression of the different geneswas normalized byGAPDHor-actinwith identical results. Data
are expressed in reference to 6-month-old WT mice. Significance was analyzed by one-way ANOVA followed by Tukey’s test (*p 0.05). D, The mRNA expression levels of TNF- and iNOS were
quantitatively determined in 6-, 12-, and 18-month-old WT and PS1xAPP hippocampi. For each age and mice group, 10 animals were used. Data (mean SD) between mice groups (WT and
PS1xAPP) and ages were compared by one-way ANOVA (TNF-, F(5,54) 91.42; p 0.0001; iNOS F(5,54) 57.03, p 0.0001) followed by Tukey’s test. Significance ( p 0.05) was indicated in
the figure. Scale bars: a1, a2, 100m; insets, 20m.
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toxic markers were significantly altered. Only the expression of
Il-1wasmoderately increased at this age. This absence of induc-
tion in the expression of cytotoxic factors occurred despite clear
microglial activation (Fig. 1A, a1; supplemental Fig. 1, available
at www.jneurosci.org as supplemental material). Thus, we next
tested whether these early activated microglial cells could display
a different phenotype. We determined the expression of YM-1
and Arg-1 genes, considered markers of the alternative differen-
tiation in peripheral macrophages (Edwards et al., 2006). Results
(Fig. 1C) demonstrated the existence of a clear induction in the
expression of YM-1mRNAat 6months of age. TheYM-1positive
cells were exclusively located surrounding and infiltrating the A
plaques (supplemental Fig. 2A, a1, available at www.jneurosci.
org as supplemental material) and were identified as microglial
cells, demonstrated by its colocalization with Tomato Lectin
(supplemental Fig. 2A, a3–5, available at www.jneurosci.org as
supplemental material). However, the expression of Arg-1 was
not altered at any age (Fig. 1C).
However, at this early age, confocal laser microscopy demon-
strated the existence of A phagocytosis, as judged by the pres-
ence of intracellular 6E10 immunostaining in Tomato Lectin
positive cells, surrounding theA plaques (supplemental Fig. 2B,
b1–3, available at www.jneurosci.org as supplemental material).
Pseudo-3D reconstruction of 6E10-Tomato Lectin labeled con-
focal images confirmed this observation (supplemental Fig. 2B,
b4, available at www.jneurosci.org as supplemental material).
A complete different scenario was observed in 18-month-old
PS1xAPP hippocampus (Fig. 1A). At this old age, we have ob-
served a patent further increase in the expression and density of
activated CD11b-positive cells (supplemental Fig. 1A,C, avail-
able at www.jneurosci.org as supplemental material). These
CD11b positive cells showed a widespread distribution, around
plaques and also in areas free of A plaques (Fig. 1A, a2; supple-
mental Fig. 1C, c3,c6, available at www.jneurosci.org as supple-
mental material). Importantly, these inter-A plaquesmicroglial
cells also exhibited an activatedmorphologywithmarked cellular
hypertrophy and thicker and shorter processes (Fig. 1A, compare
a2, inset, a1, inset). This widespread interplaque microglial acti-
vation was also verified by quantifying (using stereology) the
activated CD11b-positive microglia (morphologically discrimi-
nated) in 6 and 18month PS1xAPPCA1 region. As expected, few
interplaque activated microglial cells were detected at 6 months
of age whereas, at 18 months, a highly significant increase was
observed (199.80  54.60 cell/mm3 vs 1020.51  143.22 cell/
mm3, n  3, for 6- and 18-month-old, respectively; p  0.05).
Furthermore, this widespread activation of microglial cells was
coincident with a prominent increase in the expression of TNF-
and TNF- related factors (TRAIL and FASL), compared with
6-month-old Ps1xAPP mice. Similarly, the expression of iNOS
mRNA and, more attenuated Cox2 and Nox1 mRNAs, was also
significantly increased at this advanced age (Fig. 1B). However,
the expression of the alternative marker YM-1 remained elevated
in 18-month-old tg mice (Fig. 1C) and YM-1 positive microglia
could be observed surrounding the A plaques at this old age
(supplemental Fig. 2A, a2, available at www.jneurosci.org as sup-
plemental material).
The expression of TNF- and iNOS was also quantified in 6-,
12- and 18-month-old PS1xAPP, tomore precisely determine the
age of the microglial phenotypic switch. As shown (Fig. 1D), the
expression of TNF- and iNOS was not significantly altered
(compared with WT) in 6- and 12-month-old tg mice (although
at 12 months a moderate increase in the TNF- expression was
observed). However, a remarkable induction in the expression of
both TNF- and iNOS was detected in 18-month-old PS1xAPP
mice (Fig. 1D). Thus, the classic microglial activation seemed to
be predominantly restricted to old ages.
The cellular origin of TNF-, in 18-month-old PS1xAPP, was
then determined by immunocytochemistry (Fig. 2A, a2; com-
pare a4, a1,a3). TNF- positive cells, displaying a clearmicroglial
morphology (Fig. 2A, a5), were located in all hippocampal layers
except in the vicinity of A plaques, that appeared clearly immu-
nonegative (Fig. 2A, a2). In fact, as shown in Figure 2A–a6,
Congo red positive plaques were surrounded by a TNF- immu-
nonegative perimeter. As described in Figure 1 and supplemental
Fig. 1C–c6 (available at www.jneurosci.org as supplemental ma-
terial), there was a cluster of activated microglial cells in close
contact with A plaques; however, TNF- positivemicroglia was
mainly nonassociated to the amyloid plaques. This suggests the
existence of, at least, two different activated microglial popula-
tions in aged PS1xAPP mice. To test this proposition, we per-
formed Tomato Lectin labeling on sections previously immuno-
stained for TNF- and Congo Red. In this particular case, we did
not use confocal microscopy because of the high tissue autofluo-
rescence in aged animals. In any case, as shown (Fig. 2A, a7), the
CongoRed stained plaques, aswell as cells immediately in contact
with the plaques, were TNF--negative. However, these TNF-
negative cells surrounding plaques were stained with Tomato
Lectin, demonstrated their microglial origin (Fig. 2A, a8). Fur-
thermore, a close inspection of the Congo Red-TNF- double
labeled sections revealed the absence of TNF- immunopositive
processes infiltrating the A plaques (Fig. 2A, a7) whereas the
same plaque, counterstained with Tomato Lectin displayed a
clear infiltration by microglial prolongations (Fig. 2A, a8). Sim-
ilar results were obtained using YM-1 (data not shown)
Concerning to iNOS expression, immunohistochemical ex-
periments demonstrated the existence of few iNOS immunopo-
sitive cells in 6-month-old PS1xAPP hippocampus, restricted to
certain areas, such as stratum oriens and hilus (Fig. 2B, b1,b2).
The number of iNOS immunopositive cells increased markedly
at 18 months, compared with age-matched WT (Fig. 2B, com-
pare b3, b4, b6) or 6monthWT (Fig. 2, b5) orPS1xAPPmice (Fig.
2B, b1,b2). As also shown in Figure 2B, the iNOS-positive cells
displayed an astroglial appearance. The astroglial origin of iNOS
was confirmed by double GFAP-iNOS labeling and confocal mi-
croscopy (Fig. 2B, b7–b9). Furthermore, at 18 months of age,
iNOS containing astroglial cells were widely distributed in all
layers of the hippocampus and not restricted to the A plaques
(Fig. 2B, b3). The induction of iNOS expression by astrocytes,
because of TNF- and/or TRAIL, has been previously reported
(Akama and Van Eldik, 2000; Cantarella et al., 2008).
Together, our data demonstrated that the apparition of theA
plaques (at early ages in this model) determined the microglial
activation restricted to the A plaques. These active microglial
cells adopted a, perhaps incomplete, alternative phenotype
(YM-1 positive) and were TNF- negative. This alternative acti-
vatedmicroglial cells displayed A phagocytic capabilities. How-
ever, at 18months of age,microglial activationwas expanded into
hippocampal areas free of plaques showing, in this case, a classic
proinflammatory phenotype, with the expression of potential cy-
totoxic factors. This cytotoxic environment was also coincident
with a significant loss of pyramidal cells in this model (supple-
mental Fig. 3, available at www.jneurosci.org as supplemental
material). Nevertheless, the microglia surrounding plaques
seemed to keep expressing the alternative phenotype. The possi-
ble A phagocytosis, at old ages, was not assessed because of the
high tissue autofluorescence in these animals. However, we also
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observed an age-dependent increase in both the number and size
of A plaques (supplemental Fig. 1E, available at www.
jneurosci.org as supplemental material). This increase in the
plaque size might reflect a diminution in the microgial phago-
cytic capability.
Infiltration of CD3 positive T-cells in aged PS1xAPPmice
We next investigated the possible cause(s) that determine the
microglial activation at old ages. The generalized glial activation,
observed at 18 months of age in this AD model, could be attrib-
utable to the infiltration of peripheral T-cells into the hippocam-
pal parenchyma. The recruitment of CD4	 Th1-cells in experi-
mental autoimmune encephalomyelitis (EAE; a disease similar to
human multiple sclerosis) induced the production of, among
other cytotoxic factors, TNF- (Dhib-Jalbut et al., 2006; Weaver
et al., 2007). In consequence, we first determined the possible
infiltration of T cells in PS1xAPPmice by examining the presence
CD3-positive cells. As shown (Fig. 3A, a3) in 6-month-old
PS1xAPPmice fewCD3-positive cells were observed.On the con-
trary, in 18-month-old PS1xAPP, numerous CD3 immunoposi-
tive cells were clearly detected (Fig. 3A, a2). The presence of
CD3-positive cells was observed in all layers of the hippocampus,
although they were more abundant around some plaques and
close to the hippocampal fissure (Fig. 3A, a2,a4). However, in
WT mice very few CD3-positive cells were observed even at ad-
vanced ages (Fig. 3A, a1).
Because the T-cells couldmodify themicroglial phenotype, as
it was observed in 18-month-old PS1xAPP mice, we also deter-
mined the mRNA expression of interleukins, or key factors, im-
plicated in the different polarization linage of the T cells. In this
sense, we have quantified the expression of IL-12p35 and IFN-
gamma (proinflammatory Th1 cells); IL-23 and IL-17 (proin-
Figure 2. Expression of TNF- and iNOS in 18-month-old PS1xAPP hippocampus. A, The expression of TNF-, in 18-month-oldWT and PS1xAPPmice, was assessed by immunohistochemistry.
TNF- immunoreactivity was low inWTmice (a1, a3), whereas a prominent immunoreactivity was observed in PS1xAPP (a2, a4 ). The TNF- positive cells displayed amicroglial phenotype (a5).
Importantly, the TNF- immunoreactivity waswidespread found in all layers of the hippocampus; however, the A plaques border zone appeared immunonegative for TNF- (a6 ). Sections from
18-month-old PS1xAPPmicewere first immunostainedwith anti-TNF- antibody followed by Congo Red staining (a7 ). These double labeled sectionswere photographed and then counterstained
with Tomato Lectin (a8). As shown, the A plaques (stained by Congo-red) were surrounded and infiltrated by TNF- immunonegative and Tomato-lectin immunopositive microglia cells (a8).
Scale bars:a1,a2, 500m;a3,a4, 100m;a5, 20m;a6–a8, 100m.B, Immunostaining of iNOS expressing cells in 6- (b1,b2) and 18-month-old (b3,b4 ) PS1xAPPmice. At 6months of age,
a limited expression, restricted to stratus oriens and hilus, was observed. In 18-month-old PS1xAPP, the iNOS positive cells were observed in all hippocampal layers. A faint immunostaining was
observed inWTmice of 6months and, relatively more intense, 18months of age (b5, b6 ). Double iNOS-GFAP immunofluorescence labeling and confocal laser microscopy (b7–b9) demonstrated
the localization of iNOS in astroglial cells. Scale bars: b1–b6, 100m; b7–b9, 20m.
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flammatory Th17 cells); IL-10 and TGF-1 (Treg) and IL-4
(characteristic of anti-inflammatory Th2 response). Unexpect-
edly (Fig. 3B), absolutely no differences (compared with WT
mice) were observed in the mRNA expression of any of the Th1/
Th17 cell response interleukins. However, the expression of IL-
10, TGF--1 and, more patently, IL-4 was highly increased in
PS1xAPPmice. This response, in conjunction with the moderate
increase in the expression of IL-10 and TGF-1 could represent a
strong adaptive anti-inflammatory response (Th2 and Treg).
Thus, it is unlikely that this response couldmediate the induction
in the expression of cytotoxic factors by the activated microglial
cells. It is noteworthy that the expression of IL-4 mRNA was also
upregulated in 6-month-old PS1xAPPmice.
The expression of IL4 was further studied, by immunohis-
tochemistry, in 6- and 18-month-old PS1xAPP mice. At 6
months of age (Fig. 3C, c1), IL-4-positive punctated structures
were localized predominantly around amyloid deposits
whereas, in 18-month-old tg mice (data not shown), IL-4 pos-
itive cells were located around plaques and as isolated small
rounded cells. Double immunofluorescence and confocal la-
ser microscopy, in 6-month-old PS1xAPP mice, determined
that neither activated microglia surrounding plaques or APP
positive principal cells expressed IL-4 (data not shown). In-
stead the IL-4 immunoreactivity colocalized with GFAP posi-
tive (Fig. 3C, c2–c4) and reactive (as judged by the hypertro-
phic cell body and prolongations) astroglial cells. These
reactive astrocytes were located in close association with A
deposits (data not shown).
Concerning to the CD3 infiltration observed at older ages (18
months), we cannot directly assess the coexpression with IL-4 by
confocal microscopy. However, we have indeed identified CD3-
IL-4 coexpressing cells in 12-month-old PS1xAPPmice (Fig. 3C,
c5–c7). In these middle age tg mice, the infiltration of CD3 pos-
itive cells was lower than that observed at 18 months (data not
shown). However, and despite this limitation, all identified CD3-
positive cells infiltrating the hippocampal parenchyma were also
IL-4 positive.
Figure 3. Infiltrated CD3 positive cells in 18-month-old PS1xAPP hippocampus predominantly developed a Th2 response. A, Double labeling for anti-CD3 and Congo Red immunohistochemistry
demonstrated the infiltration of CD3-positive cells in hippocampus of 18 month PS1xAPPmice (a2, a4 ), whereas the presence of CD3 cells was scarce in 18 monthWT (a1) or in 6 month PS1xAPP
mice (a3). The infiltrated CD3 cells were preferential, but not exclusively located around some A plaques (a4 ). B, The expression of different interleukin mediators, IFN-gamma and TGF-1,
considered representative of the different adaptive T-mediated immune responses, were determined in 6- and 18-month-oldWT and PS1xAPPmice (n 10 per group). ComparedwithWT (using
one-way ANOVA), only the expression of IL-10, TGF- and, more prominently, IL-4 were significantly induced in PS1xAPP mice. Interestingly, the expression of IL-4 also displayed a significant
increased in6-month-oldPS1xAPP.C, At 6months of age (c1), IL-4punctate immunostainingwas concentratedaroundAplaques. DoubleGFAP-IL4 immunolabeling and confocal lasermicroscopy
(c2– c4 ) revealed that activated astroglial cells expressed this interleukin. In 12-month-old PS1xAPPmice, all infiltrating CD3-positive cells were also immunoreactive for anti-IL4 (c5– c7 ). Scale
bars: a1–a3, 200m; a4, 100m; c1, 25m; c2– c4, 5m; c5-c7, 5m.
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Soluble oligomeric A could be responsible for the
generalized microglial activation at advanced ages
Finally, we investigated the presence of extracellular soluble A
species [monomers or amyloid–beta-derived diffusible ligands
(ADDLs)/oligomers] as putative inductors of the age-dependent
glial generalized activation. We have first determined, by sand-
wich ELISA, the A42 content in the soluble fractions (S1 frac-
tions, see Materials and Methods). The A42 levels in 6-month-
old PS1xAPP hippocampus was maintained at very low levels
(6.7 1.3 pmol/mg protein, n 4), despite abundant A depos-
its in this model (Fig. 1A; supplemental Fig. 1C,D, available at
www.jneurosci.org as supplemental material). However, at 18
months we observed a dramatic increase in the A42 content. In
fact, this soluble A42 increased 15-fold (86.9  54.2 pmol/mg
protein, n  4; p  0.05), in average, compared with 6-month-
old PS1xAPP. This increase was notably higher than the twofold
increase in the plaque loading, observed between 6- and 18-
month-old PS1xAPP (supplemental Fig. 1D, available at www.
jneurosci.org as supplemental material).
We next tested the presence of A oligomeric forms in the
extracellular, soluble fractions. It is well known that diffusible
aggregated A forms (ADDLs/oligomers) are highly toxic (De
Felice et al., 2007). Thus, we determined the presence of these A
forms using the specific monoclonal antibody Nu-1 in dot blots
(Lambert et al., 2007). As shown in Figure 4A, quantitatively in
Figure 4B, the presence of soluble ADDLs was barely detectable
in 6- and 12-month-old PS1xAPP mice, as well as in WT mice.
However, at 18 months, the soluble extracts displayed an intense
immunoreactivity with Nu-1. Although it
was difficult to quantify this age-
dependent increase, because of the low
specific signal observed at 6 and 12
months, our estimative quantification in-
dicated the existence of 10-folds of in-
crease at 18 months of age. Moreover, we
also used A11 to corroborate the presence
of oligomeric A in these soluble extracts.
As shown in Figure 4A and quantitatively
in Figure 4B, the soluble extract from these
18 month PS1xAPPmice displayed a clear
immunoreactivity with A11, compared
with age-matched WT mice or 6 and 12
month PS1xAPP. It is also interesting that,
usingA11,we detected a small increase (al-
though nonsignificant) in the oligomeric
content in 12-month-old PS1xAPP. In
conclusion, the amount of Nu-1 and A11
immunopositive oligomeric A displayed
a clear age-dependent increase in the solu-
ble extract of PS1xAPPmice. At 18months
of age, the presence of these immunoposi-
tive Nu-1 and A11 oligomers was clearly
patent.
Although SDS-PAGE is a reductive
technique and as such cannot provide an
accurate reflection of the noncovalently
associated A oligomers (Hepler et al.,
2006), the presence of the soluble oligo-
meric A forms was also assayed in West-
ern blots using 6E10. As shown (Fig. 4C), a
prominent APPs band was clearly de-
tected in 6-, 12-, and 18-month-old
PS1xAPP mice. At 6 and 12 months, very
small amount of low-n aggregated A was detected, under the
conditions used for these experiments. A faint band, correspond-
ing to 5- or 6-mer A could be barely observed in 6- and 12-
month-old PS1xAPP mice. However, as expected from the dot
blot analysis, in 18month PS1xAPPmicemultiple A formswere
clearly distinguished. The observed 6E10-positive bands corre-
sponded with the reported Mr for the oligomeric A forms, de-
tected byWestern blots (see Lambert et al., 2007), and also similar
to soluble oligomers identified in other aged tg models (Lesne´ et
al., 2006). In fact, according with the Mr, three predominant A
forms were identified in the soluble extracts; monomer, 6-mer
and 12-mer. Although the 12-mer could also be present, in lower
amount, in 6 and 12 month mice (Fig. 4C), these low Mr oli-
gomers were barely detectable in the soluble extract from 6- and
12-month-old PS1xAPP. We cannot discard that other high mo-
lecular weight forms were also increased in 18-month-old tg
mice. Independently of the oligomeric state of A, these data
clearly demonstrated the existence of a marked increase in the
soluble A forms in our 18-month-old PS1xAPP mice popula-
tion. Therefore, the presence of these ADDLs/oligomeric A
forms could be implicated in the classic microglial activation,
observed in our 18-month-old PS1xAPP cohort.
To validate this hypothesis, we next tested, in vitro using as-
tromicroglial cultures, the effect of monomeric and oligomeric
A42 forms in the expression of TNF-. LPS was used as a posi-
tive control. The results (Fig. 5A) demonstrated that LPS and,
dose-dependently, the oligomeric A42 strongly stimulated the
expression of the proinflammatory TNF-. Interestingly, equiv-
Figure 4. The increase in the soluble oligomeric A, in 18month PS1xAPP hippocampus. A, Representative dot blots demon-
strating the presence of oligomeric A in the soluble fractions. In these experiments we used the conformational-specific anti-
bodies Nu-1 and A11. For each blot, the soluble extracts form the different age and group (WT and PS1xAPP) mice (n 4 per age
and group)were used in different combinations. These experimentswere repeated twice.B, Quantitative analysis of PS1xAPP dot
blots usingNu-1andA11. The immunoreactivity of thedifferentPS1xAPPmicewasnormalizedby6-month-oldPS1xAPPmiceand
displayed individually or asmean SD.C, RepresentativeWesternblot, using6E10, of thedifferent soluble fractions from6-, 12-,
and 18-month-old PS1xAPPmice. These experiments were repeated three times with similar results.
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alent concentrations of monomeric A42
were totally ineffective stimulating the
TNF- expression in these cultures. Based
on these data, we predicted that the soluble
extracts from 18-month-old PS1xAPP
mice should also stimulate the expression
of TNF- in the glial cultures. Thus, we
tested the stimulatory effect of increasing
amounts of soluble proteins (ranging from
5 to 100 g of protein), obtained from 6-
and 18-month-old WT and PS1xAPP
mice. As shown, the soluble fractions from
young WT and PS1xAPP mice produced
no apparent effect on the expression of
TNF- (Fig. 5B). Similarly, the soluble
fractions from 18-month-old WT mice
were also ineffective stimulating the TNF-
production. However, the soluble fractions
derived from 18-month-old PS1xAPP mice
produced a potent dose-dependent stimula-
tion in the expression of TNF- in these as-
tromicroglial cultures (Fig. 5B).
Finally, if the soluble oligomeric A in
the S1 fractions was indeed the causative
agent of the TNF- stimulation, this effect
should be avoided by immunodepletion of
the supernatant using specific antibodies.
To test this point, the A content of the S1
fractions, derived from 18-month-old
PS1xAPP mice (n  3), was immunode-
pleted by three sequential immunopre-
cipitations using either the mAb 6E10
(that should recognized the total soluble
A) or the conformation specific poly-
clonal A11 (specific of the oligomeric A).
As shown (Fig. 5C), after immunodeple-
tion using 6E10, the induction in the
TNF- expression by these immunode-
pleted S1 fractions was deeply reduced
(from 94.60  6.02–2.87  0.90, n  3,
before and after immunodepletion, relative units normalized by
PBS effect, 1.01  0.24; p  0.05, Tukey’s test). Moreover, the
immunodepletion of the oligomeric A using A11 (Fig. 5C), also
produced an almost completed reduction in the TNF- induc-
tion by the S1 fractions (2.33 0.45, n 3, after immunodeple-
tion; p 0.05, Tukey’s test).
Discussion
Neuroinflammation is a key feature of ADpathology (Meda et al.,
2001;Dudal et al., 2004; Craft et al., 2006).However, its role is still
conflictive. Here, we have analyzed the microglial response asso-
ciated to the age-dependent amyloid pathological progression in
the hippocampus of PS1M146LxAPP751SL mice. The principal
findings are as follows. (1) At early ages (4–6 months), activated
microglia was restricted to A deposits and characterized by the
absence of induction of cytotoxic factors and by the expression of
one alternative marker (YM-1). (2) In 18-month-old, microglial
activation was expanded throughout the hippocampus, display-
ing a classical potentially cytotoxic phenotype (expressing
TNF-, FASL, TRAIL, Cox2 and Nox1). The expression of iNOS
was restricted to astrocytes. (3) Although a clear hippocampal
T-cell infiltration was detected at 18 months, these T-cells were
polarized to Th2 phenotype. (4) There was an age-dependent
increase in extracellular soluble A oligomers, whichwere potent
microglial stimulators as assessed by in vitro studies.
We observed a close spatial and temporal parallelism between
A deposits and microglial activation (Simard et al., 2006). At
early ages, activated microglia was concentrated in clusters sur-
rounding and infiltrating A plaques. In fact, few extra-plaque
microglial activation was observed. Thus, according with recent
in vivo observations (Meyer-Luehmann et al., 2008), plaques at-
tracted and stimulated microglial cells. However, activated mi-
croglia could adopt different phenotypes.Our data demonstrated
that plaque-associatedmicroglia displayed an alternative state. In
peripheralmacrophages, this phenotype was characterized by the
absence of expression of cytotoxic factors and the expression of
alternative markers (YM-1 and Arg-1) (Edwards et al., 2006).
Althoughwe have not observed the induction in Arg-1, the YM-1
expression was highly elevated inmicroglia surrounding plaques.
These results, together with the absence of significant TNF-,
TRAIL, FASL or iNOS expression led us to conclude that the
activated microglia could adopt an incomplete alternative phe-
notype. Furthermore, this alternative phenotype, associated to
A plaques, seemed to be maintained also at relative old ages. In
fact, at 18-months, the microglia surrounding A plaques was
TNF- negative and YM-1 positive. Therefore, activated micro-
Figure 5. The oligomeric A induced the TNF- expression in glial primary cultures. A, Dose–response stimulation of the
TNF- expression by oligomeric andmonomeric A42 assessed in vitro in astromicroglial cultures. PBS and LPS (1g/ml) were
used as negative and positive controls, respectively. Data are mean SD from three independent cultures and A42 prepara-
tions. B, Stimulation of the glial cultures using the S1 soluble fractions. Increasing protein amounts (from 5 to 100g) of the
different S1 fractions (6 and 18months of age;WT and PS1xAPP; n 3 per age and group) was added to the cultures. In parallel,
PBS, monomeric (20M), oligomeric A42 (20M) and LPS (1g/ml) were included as negative and positive controls, respec-
tively. For each experiment, duplicate culture wells were used. This experiment was repeated twice, using independent cultures.
Only the soluble extract from 18-month-old PS1xAPP produced the stimulation of the TNF- expression in these experiments
(asterisk; p 0.05, Tukey’s test). C, Immunodepletion experiments. In these experiments, the A content from the S1 fractions
(10g of protein) of three different 18-month-old PS1xAPPmice was immunodepleted by three sequential immunoprecipita-
tions using either 6E10-Protein G-Sepharose or A11-Protein A-Sepharose complexes. After immunodepletion, the S1 fractions
were used in stimulation experiments. In parallel, the different S1 fractions were treated with Protein G-Sepharose or Protein
A-Sepharose. We observed no differences in the TNF- stimulation between these control S1 fractions and the results were
pooled. The immunodepletion of A, by any of the antibodies used, precluded the stimulatory effect of the S1 fractions. PBS,
oligomeric A42 (20M) and LPS (1g/ml) were included as negative and positive controls, respectively.
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glia in direct apposition with A plaques adopted an alternative
phenotype, regardless of the age of the animal. This proposition
was consistent with the increased expression of IL-4. Multiple in
vitro reports have probed the influence of IL-4 in the develop-
ment of a non-proinflammatory alternative phenotype (Iribar-
ren et al., 2005; Butovsky et al., 2005; Ponomarev et al., 2007;
Lyons et al., 2007a,b). Furthermore, at early ages, the expression
of this interleukin was restricted to reactive astrocytes, closely
associated to A plaques. Similarly, at 18 months, plaques were
also surrounded by IL-4 positive astrocytes and, probably, CD3
cells. In consequence, we proposed that the alternative pheno-
type, associated toA plaques, could be because of the expression
of IL-4 by activated astrocytes and, when present, CD3-cells. We
cannot discard that A plaques could directly produce this mi-
croglial differentiation. The factor(s) that determine the astro-
glial activation remains to be investigated.
Concerning to the physiological role, the alternative activated
microglia could exert a neuroprotective function. In presence of
IL-4,microglia produces growth factors (i.e., IGF-1) (Butovsky et
al., 2006; Zhao et al., 2006). The IL-4 reduced A toxicity, in vitro
and in vivo (Butovsky et al., 2005, 2006; Iribarren et al., 2005;
Lyons et al., 2007a,b) and enhanced A phagocytosis
(Koenigsknecht-Talboo and Landreth, 2005). In agreement, we
also observed the expression of IGF-1, in the vicinity of A de-
posits (our unpublished results) and A phagocytosis by micro-
glia surrounding plaques (supplemental Fig. 2B, available at
www.jneurosci.org as supplemental material). In this sense,
Bolmont et al. (2008) have recently demonstrated the internal-
ization of A peptides by plaque-associated microglia and pro-
posed an active role in the maintenance of plaque size. Further-
more, the decrease in the early recruitment of themicroglial cells,
by genetic ablation of either TLR2 receptor, in a PS1/APP model
(Richard et al., 2008) or CCR2 in Tg2576 (El Khoury et al., 2007),
increased A42 levels, accelerated memory impairments and in-
creased vascular amyloid pathology. Thus, we propose that the
plaque-associated alternative activated microglia could limit A
toxicity directly, by phagocytosis (see also Simard et al., 2006),
maintaining low extracellular A levels. In fact, our data demon-
strated low levels of soluble A42 and oligomeric forms until
advanced ages.
Furthermore, this alternative activated microglia could also
indirectly exert a neuroprotective role by releasing growth fac-
tors, such as IGF-1. This proposition is also consistent with the
positive effects of vaccination with the Th2 adjuvant glatiramer
acetate, the concomitant increase in IL-4 expressing cells and the
reduction of A plaques (Butovsky et al., 2006).
At 18 months of age, microglia located between, not in direct
contact with A plaques, was clearly activated. Furthermore,
these interplaque microglial cells expressed TNF- (and proba-
bly other TNF- related factors), whereas the microglia closely
associated to A plaques remained TNF- negative and YM-1
positive. Thus, at old age, two functionally different activated
microglial populations should coexist, indicating the existence of
different microglial activators. In this sense, even at this old age,
there was a clear IL-4 expression surrounding plaques. Thus, and
similar to the situation observed in 6-month-old PS1xAPPmice,
plaques (directly and/or indirectly through IL-4)might stimulate
microglia to a noncytotoxic phenotype. This observation let us to
propose that the generalized microglial activation should be in-
duced by a diffusible agent.
Asmentioned, the generalmicroglial activation could reflect a
Th1/Th17 CD3-mediated response. According with previous re-
ports in AD andADmodels (Itagaki et al., 1988; Togo et al., 2002;
Stalder et al., 2005) we observed CD3-cells in 18-month-old
PS1xAPP hippocampus. However, the expression of IL-12, IL-17
and IL-23 was unchanged, compared with age-matched WT. In-
stead, we observed a considerable induction of IL-4 and IL-10
expression. Moreover, these CD3-cells also expressed IL-4. To-
gether, data strongly suggest that the infiltrated T-cells were pre-
dominantly polarized to Th2 and/or Treg states. These anti-
inflammatory Th2/Treg cells could explain the absence of
encephalitis signs in AD models (Stalder et al., 2005). Thus,
the Th2 polarization could limit the potential neurotoxic ef-
fect of the activated microglia and it is highly unlikely that
CD3 infiltration mediated the expanded microglial activation,
observed in this model.
Multiple evidences suggested that diffusible A oligomers
(ADDLs) were the toxic agents in AD. These ADDLs were exclu-
sively present in ADpatients (Gong et al., 2003; Lacor et al., 2004)
and their content increased with the disease severity (Lambert et
al., 2007). In fact, our results demonstrated the increase in soluble
A42 in 18-month-old PS1xAPP. Furthermore, our data also
probed the presence of Nu-1 and A11 immunopostive oligomers
in these soluble fractions (barely detectable at early ages). Thus,
we hypothesized that the oligomeric A was also the causative
agent of the generalizedmicroglial response at 18months. Our in
vitro experiments strongly supported this proposal. In fact, oli-
gomeric A42 highly stimulated the TNF- expression in cul-
tures, whereas monomeric A42 was ineffective. More relevant,
the soluble S1 fractions from 6-month-old WT and PS1xAPP
mice and 18-month-old WT, that lack detectable levels of oli-
gomers, were also ineffective stimulating TNF- production in
culture. However, S1 fractions from 18-month-old PS1xAPP
produced a strong TNF- induction. Moreover, the immu-
nodepletion of A, using 6E10 or A11, completely abolished the
stimulatory effect of the S1 fractions. In consequence, we pro-
posed that the generalizedmicroglial activation with a classic and
potentially cytotoxic phenotype, observed at 18months, could be
because of the accumulation of soluble oligomeric A in the
hippocampal parenchyma. Furthermore, it has been reported
that aging and/or A could decrease the neuronal expression of
microglial inhibitory factors, such as CD200, fractalkine or neu-
rotransmitters (Acetylcholine or noradrenaline) (Cardona et al.,
2006; Chitnis et al., 2007; Heneka and O’Banion, 2007; Lyons et
al., 2007a; Duan et al., 2008). Furthermore, damaged neurons
could release microglial stimulants, such as ATP, UDP or CCL21
(de Jong et al., 2005; Inoue et al., 2007). Therefore, it is possible
that the classic microglial activation in our model could reflect a
synergic effect of A oligomers, acting directly on microglia and,
indirectly, by affecting neuronal-microglial interplay.
The role of the classical microglial activation was unknown.
The neuronal toxicity to TNF-, TNF- related factors and iNOS
has been extensively probed (Cantarella et al., 2003; Lee et al.,
2004; Li et al., 2004; Medeiros et al., 2007; Uberti et al., 2007).
Indeed, in our model, we (supplemental Fig. 3, available at
www.jneurosci.org as supplemental material) and others
(Schmitz et al., 2004) have observed a significant decrease in
pyramidal cell number, coincident with the classical microglial
activation (17–18months). Although present results do not allow
establishing a direct relationship between these events, the pro-
duction of TNF-, TRAIL, FASL andNOderivates, together with
the presence of soluble A oligomers, could directly contribute to
the observed pyramidal degeneration.
In conclusion, at early ages in our ADmodel, the apparition of
A plaques determined the microglia activation to an alternative
phenotypewith, apparently, a neuroprotective role. At older ages,
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the accumulation of extracellular oligomeric A produced
marked widespreadmicroglial activation toward a classic pheno-
type and the production of cytotoxic factors. The reasons that
determined this age-dependent increase in the ADDL/oligomers
content remained unknown.
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